Merck lowers profit outlook, partly due to $200 million expected tariff hit
1. Merck lowered profit guidance by an estimated $200 million due to tariffs. 2. Adjusted earnings for 2025 projected between $8.82 and $8.97 per share. 3. Keytruda sales increased but were below analyst expectations at $7.21 billion. 4. China sales for Gardasil declined 41%, affecting overall revenue. 5. Merck remains bullish with $12 billion in U.S. manufacturing investments.